PharmaTher Sees Executive Order As Tailwind For Its Ketamine Portfolio

PharmaTher Holdings (OTCQB: PHRM) says President Trump’s April 18 executive order, could materially improve the policy environment for innovative ketamine‑based therapies. The order instructs HHS, FDA, VA, and other agencies to accelerate research and regulatory pathways for psychedelic medicines targeting severe, treatment‑resistant conditions, with an emphasis on trial participation, data‑sharing, and real‑world evidence.

How this ties into PharmaTher’s ketamine strategy

The company argues the order reinforces the strategic value of its ketamine franchise, which spans an FDA‑approved injectable product (KETARx), multiple orphan designations and next‑generation formulations. Management highlights four key assets it believes stand to benefit:

• A portfolio of specialty ketamine programs built on a 505(b)(2) pathway for neuropsychiatric and neurological indications.
• A microneedle patch platform (PharmaPatch) developed for controlled, sustained delivery of ketamine and other actives.
• The KetaVault partnership portal, positioned as a hub for ketamine‑focused collaborations and real‑world data.
• Ongoing economic participation in a sold ketamine ANDA via milestones and profit‑sharing, giving capital‑light exposure to the generic injectable market.

PharmaTher believes the executive order’s focus on serious mental illness, veteran care and accelerated access aligns closely with its ketamine thesis in depression, suicidality and other difficult‑to‑treat conditions.

Capital-light, partnership-driven model

The company continues to emphasize a capital‑light strategy: monetizing its approved ketamine asset via partners while concentrating internal resources on higher‑value, next‑gen programs such as long‑acting injectable (LAI) ketamine for treatment‑resistant depression. By tying its development plans to the FDA’s 505(b)(2) framework and emerging real‑world evidence guidance, PharmaTher argues it can shorten timelines and expand its partnering appeal without carrying the full cost of large Phase 3 programs alone.

Investor perspective and comps

From an investor standpoint, the executive order doesn’t remove clinical or regulatory risk, but it does suggest a friendlier U.S. stance toward psychedelic‑adjacent therapies, especially when backed by robust data and controlled delivery. PharmaTher’s mix of approved product exposure, ANDA economics and pipeline optionality positions it differently from pure‑play psychedelic developers such as Compass Pathways (CMPS) and Cybin (CYBN), while still riding the same broad policy and mental‑health tailwinds.